# Cencora vs Takeda Pharmaceutical: stocks compared

URL: https://funkfolio.com/compare/cor-vs-tak

> Cencora ($66.9B, P/E 19.5) and Takeda Pharmaceutical ($69.1B, P/E 309) compared: size, valuation, margins, debt, cash and price change.

---

## Cencora vs Takeda Pharmaceutical

Cencora (COR), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Takeda Pharmaceutical is worth $69.1B on the stock market and Cencora $66.9B: Takeda Pharmaceutical is valued at 3% more. Cencora trades at 19.5 times earnings and Takeda Pharmaceutical at 309; operating margins in their latest fiscal years were 0.82% and 0.14%. Over the past year Cencora's share price has moved -1.30% and Takeda Pharmaceutical's +53.4%.

### Key facts

- **Cencora market value:** $66.9B
- **Takeda Pharmaceutical market value:** $69.1B
- **Cencora P/E:** 19.5
- **Takeda Pharmaceutical P/E:** 309
- **Cencora revenue:** $321.3B FY to 2025-09-30
- **Takeda Pharmaceutical revenue:** $28.2B FY to 2026-03-31
- **Superinvestors holding both:** 0

Market values as of 18 Nov 2026, 01:53 UTC.

Cencora vs Takeda Pharmaceutical: every measure side by side

| Measure | Cencora | Takeda Pharmaceutical |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Japan |
| Fiscal year ends | 2025-09-30 | 2026-03-31 |
| Size |  |  |
| Market cap | $66.9B lower | $69.1B higher |
| Revenue | $321.3B higher | $28.2B lower |
| Earnings | $1.6B higher | -$954.4M lower |
| Employees | — | 47,029 |
| Total assets | $76.6B lower | $97.1B higher |
| Valuation |  |  |
| P/E | 19.5 lower | 309 higher |
| P/S | 0.2 lower | 2.5 higher |
| P/B | 18.2 | — |
| Dividend yield | 0.67% | — |
| Profitability |  |  |
| Operating margin | 0.82% higher | 0.14% lower |
| Balance sheet |  |  |
| Net assets | $1.5B lower | $46.5B higher |
| Total liabilities | $74.8B higher | $50.6B lower |
| Total debt | $7.7B lower | $30.6B higher |
| Cash on hand | $4.4B higher | $3.7B lower |
| Price change |  |  |
| Today | -1.79% lower | +0.23% higher |
| 1 year | -1.30% lower | +53.4% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Cencora 97.8, Takeda Pharmaceutical 152.7.

- Cencora (COR)
- Takeda Pharmaceutical (TAK)

Cencora and Takeda Pharmaceutical share prices over one year, rebased to 100: Cencora ends at 97.8, Takeda Pharmaceutical at 152.7.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | COR | TAK |
| --- | --- | --- |
| Nov 28, 2025 | 101.1 | 102.0 |
| Dec 31, 2025 | 92.5 | 110.3 |
| Jan 30, 2026 | 98.4 | 121.9 |
| Feb 27, 2026 | 102.0 | 132.6 |
| Mar 31, 2026 | 86.1 | 131.0 |
| Apr 30, 2026 | 84.4 | 118.0 |
| May 29, 2026 | 73.8 | 112.9 |
| Jun 30, 2026 | 77.5 | 113.4 |
| Jul 31, 2026 | 85.3 | 120.9 |
| Aug 31, 2026 | 88.7 | 127.2 |
| Sep 30, 2026 | 82.3 | 128.6 |
| Oct 30, 2026 | 90.6 | 147.9 |
| Nov 16, 2026 | 97.8 | 152.7 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (0)

None of the tracked investors.

#### Cencora only (3)

- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.3%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2%

#### Takeda Pharmaceutical only (2)

- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.5%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio. [Who owns COR](https://funkfolio.com/stock/COR/superinvestors) · [Who owns TAK](https://funkfolio.com/stock/TAK/superinvestors)

### More on Cencora

- [Cencora (COR) stock page](https://funkfolio.com/stock/COR)
- [Cencora market cap](https://funkfolio.com/stock/COR/market-cap)
- [Cencora revenue](https://funkfolio.com/stock/COR/revenue)
- [Cencora P/E ratio](https://funkfolio.com/stock/COR/pe-ratio)
- [Cencora operating margin](https://funkfolio.com/stock/COR/operating-margin)
- [Cencora total debt](https://funkfolio.com/stock/COR/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Takeda Pharmaceutical

- [Takeda Pharmaceutical (TAK) stock page](https://funkfolio.com/stock/TAK)
- [Takeda Pharmaceutical market cap](https://funkfolio.com/stock/TAK/market-cap)
- [Takeda Pharmaceutical revenue](https://funkfolio.com/stock/TAK/revenue)
- [Takeda Pharmaceutical P/E ratio](https://funkfolio.com/stock/TAK/pe-ratio)
- [Takeda Pharmaceutical operating margin](https://funkfolio.com/stock/TAK/operating-margin)
- [Takeda Pharmaceutical total debt](https://funkfolio.com/stock/TAK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Cencora against its closest peers

- [Cencora vs Boston Scientific](https://funkfolio.com/compare/bsx-vs-cor)
- [Cencora vs Cardinal Health](https://funkfolio.com/compare/cah-vs-cor)
- [Cencora vs argenx](https://funkfolio.com/compare/argx-vs-cor)

#### Takeda Pharmaceutical against its closest peers

- [Takeda Pharmaceutical vs Boston Scientific](https://funkfolio.com/compare/bsx-vs-tak)
- [Takeda Pharmaceutical vs Cardinal Health](https://funkfolio.com/compare/cah-vs-tak)
- [Takeda Pharmaceutical vs argenx](https://funkfolio.com/compare/argx-vs-tak)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Cencora or Takeda Pharmaceutical?**

By market value, Takeda Pharmaceutical is the larger: $69.1B against $66.9B for Cencora. By revenue in its latest fiscal year, Cencora is the larger: $321.3B against $28.2B for Takeda Pharmaceutical.

**Which has the higher P/E ratio?**

Takeda Pharmaceutical: 309, against 19.5 for Cencora. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Cencora: 0.82%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Takeda Pharmaceutical: $30.6B, against $7.7B for Cencora. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Cencora and Takeda Pharmaceutical?**

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Cencora and 2 hold Takeda Pharmaceutical.

### Cite this page

Funkfolio, “Cencora vs Takeda Pharmaceutical”, data as of 18 November 2026. https://funkfolio.com/compare/cor-vs-tak

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
